NCT00976469已完成1 期
An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of Two Different Dose Levels of H1N1 Pandemic Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 400
- 试验地点
- 8
- 主要终点
- To assess the immune response to two different dose levels of a H1N1 pandemic influenza vaccine in healthy infants, children and adolescents aged 6 months to 17 years
研究概览
简要总结
The purpose of this study is to determine the preferred dose of H1N1 pandemic influenza vaccine in a pediatric population, aged 6 months to 17 years, based upon assessments of immunogenicity and safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 6 Months 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Written informed consent provided by subject's parent(s) / legal guardian(s) (according to national law)
- •Written assent provided by subject according to age and capacity of understanding
- •Subject is 9 to 17 years (Stratum A), 3 to 8 years (Stratum B), 12 to 35 months (Stratum C) or 6 to 11 months of age (Stratum D) at the time of screening
- •Subject was born at full term of pregnancy (>= 37 weeks) with a birth weight >= 2 kg (Strata C and D) Subject / parent(s) / legal guardian(s) understand(s) the nature of the study and is / are willing to comply with the requirements of the protocol (e.g. return for follow-up visits, completion of the subject diary)
- •If female of childbearing potential, subject presents with a negative urine pregnancy test within 24 hours prior to the first vaccination and agrees to employ adequate birth control measures for the duration of the study
- •Subject is generally healthy, as determined by the investigator's clinical judgment through collection of medical history and the performance of a physical examination
- •Subject is physically and mentally capable of participating in the study
排除标准
- •Subject has participated in another clinical study involving an investigational drug, biological product or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an investigational drug, biological product or device during the course of this study
- •Subject has a history of exposure to A/H1N1/California/07/2009 virus or a history of vaccination with A/H1N1/California/07/2009 antigen or a closely related influenza virus antigen
- •Subject has any inherited or acquired immune deficiency
- •Subject currently has or has a recent history of significant neurological, cardiovascular or pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder
- •Subject has a history of testing positive for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HBsAg) or Hepatitis C Virus (HCV). No confirmatory testing for previous infection with these viruses will be conducted as part of this clinical study.
- •Subject has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that could be expected to influence immune response. Such treatment includes, but is not limited to systemic or high dose inhaled corticosteroids, radiation treatment, or other immunosuppressive or cytotoxic drugs.
- •Subject has a history of severe allergic reactions or anaphylaxis
- •Subject has a rash, dermatologic condition or tattoos which might interfere with injection site reaction rating
- •Subject has received a blood transfusion or immunoglobulins within 90 days of study entry
- •Subject has received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study Subject has functional or surgical asplenia
- •Subject has a known or suspected problem with alcohol or drug abuse
- •Subject or one of subject's parent(s) / legal guardian(s) is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, siblings, partner/spouse, parents) as well as employees of the investigator or site personnel conducting the study
- •Subject is pregnant or lactating
结局指标
主要结局
To assess the immune response to two different dose levels of a H1N1 pandemic influenza vaccine in healthy infants, children and adolescents aged 6 months to 17 years
时间窗: 42 days
To assess the safety of two different dose levels of a H1N1 pandemic influenza vaccine in healthy infants, children and adolescents aged 6 months to 17 years
时间窗: Within 7 days after each vaccination
次要结局
未报告次要终点
研究者
研究点 (8)
Loading locations...
相似试验
已完成
1 期
Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in AdultsAvian InfluenzaInfluenzaNCT00895544Resilience Government Services, Inc.231
已完成
1 期
Study of the Safety and Immunogenicity of H1N1 VaccineH1N1 FluNCT01177202Fraunhofer, Center for Molecular Biotechnology80
已完成
1 期
A/H1N1 Immunogenicity and Safety in AdultsPandemic InfluenzaInfluenzaNCT00959465Resilience Government Services, Inc.408
已完成
2 期
Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 VaccineInfluenza ImmunizationHealthy VolunteersNCT04969276Sanofi Pasteur, a Sanofi Company306
已完成
1 期
A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy AdultsInfluenzaNCT00942071University of Oxford58